JAB-23E73

· Jacobio Pharmaceuticals Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for JAB-23E73, covering 2026-01-16 to 2026-01-20. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration [Phase 1, Phase 2]

See pricing